NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

September 25, 2023

Continuing its discussion on clinical trials in multiple myeloma, the panel emphasizes the impact that data may have on the real-world treatment landscape.

September 22, 2023

Bhavana Pothuri, MD, discusses the use of antibody-drug conjugates in patients with ovarian cancer and AEs to be aware of when treating patients with these therapies.

September 19, 2023

Experts on non–small cell lung cancer discuss recent data on brigatinib and lorlatinib for the treatment of patients with ALK rearrangements.

September 19, 2023

Luis Raez, MD, offers insights on how co-mutations in STK11 or KEAP1 impact the use of immunotherapies in KRAS G12C–mutant non–small cell lung cancer.

September 19, 2023

Bhavana Pothuri, MD, discusses treatment considerations for patients in tough-to-treat subgroups of ovarian cancer based on currently available data.

September 18, 2023

Key opinion leaders in multiple myeloma management elucidate the value of clinical trials and share enthusiasm for improving enrollment when possible.

September 18, 2023

A focused discussion on the regulatory aspects of drug testing and approval, globally, with respect to the setting of multiple myeloma management.

September 12, 2023

In this third episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, share how they would best utilize genetic testing results obtained from endoscopic ultrasound–guided biopsies in pancreatic ductal adenocarcinomas.

September 12, 2023

Joshua K. Sabari, MD, discusses adagrasib as a treatment of patients with NSCLC with KRAS G12C mutations, and provides insight on treating patients who have progressed on prior KRAS G12C inhibitors.

September 12, 2023

Expert panelists review the CodeBreaK trials focused on sotorasib in the treatment of patients with KRAS G12C-mutant non–small cell lung cancer.

September 11, 2023

Expert panelists consider best methods in educating patients on their options for therapy following a diagnosis of multiple myeloma.

September 11, 2023

Comprehensive insight to disparities that may impact a patient’s access to therapy for multiple myeloma and how these may be overcome.

September 07, 2023

Bhavana Pothuri, MD, discusses the promise of the phase 3 NRG-GY018 and RUBY trials in patients with endometrial cancer.

September 05, 2023

In this second episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, discuss the techniques used such as endoscopic ultrasound–guided biopsies to collect adequate tissue to perform genomic analyses in pancreatic cancer, and the likelihood for finding actionable mutations in this population.

September 05, 2023

Shared insight on the use of first-generation EGFR tyrosine kinase inhibitors and the role of immunotherapy in treating patients with NSCLC with uncommon EGFR mutations.

September 05, 2023

Julie R. Brahmer, MD, discusses treatment considerations when choosing between afatinib and osimertinib in patients with NSCLC with rare EGFR mutations.

September 04, 2023

Panelists share a brief discussion on the current treatment armamentarium available to patients with newly diagnosed multiple myeloma.

September 04, 2023

Experts in multiple myeloma management consider essential tests that aid in the diagnosis and treatment of newly presenting patients.

August 29, 2023

In this first episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, discuss how endoscopic ultrasound has changed the diagnosis of pancreatic cancer and how it may also be utilized to guide personalized treatment in nonmetastatic adenocarcinomas.

August 29, 2023

Key opinion leaders on non–small cell lung cancer review treatment options for patients with EGFR mutations.